Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib versus ibrutinib in previously treated high-risk chronic lymphocytic leukemia
NL-OMON54575Phase 3Active, not recruiting
- Sponsor
- Acerta Pharma
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Acalabrutinib arm with Ibrutinib arm (2 arms). Primary endpoint: Progression-free survival. Started Sep 2015; status: active, not recruiting.
02
Drugs
acalabrutinibibrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on NL-OMON54575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54575.